Vasile Popa, MD
Neurology · Fort Smith, ARNPI 1508245572
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,036 of the $7,772 with a category attached, or 64.8%. 40 manufacturers reported payments, led by Livanova USA, Inc. at 38.9% of the total. Reporting peaked in 2024 at $4,216 and has fallen 86.4% since, to $574 in 2025.
Across 228 payments — averaging $34.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$3K
- Bristol Myers Squibb$412
- SK Life Science, Inc.$407
- Teva Pharmaceuticals USA, Inc.$371
- AbbVie$367
- Pfizer$307
- plus $3K from 34 others
What the payments were for
- Travel & lodging$2,62334%
- Food & beverage$5,03665%
- Education$1141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$2,980
- ZEPOSIA$252
How this compares
$7,772 in reported general payments places this provider in the 70th percentile of 93 neurology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 115 | $171,860 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 11 | $136,623 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 13 | $107,514 |
| ZeposiaOzanimod Hydrochloride | 12 | $90,463 |
| AustedoDeutetrabenazine | 13 | $88,094 |
| UbrelvyUbrogepant | 56 | $85,090 |
| Emgality PenGalcanezumab-Gnlm | 80 | $79,751 |
| GocovriAmantadine Hcl | 21 | $67,293 |
| EliquisApixaban | 53 | $54,254 |
| Aimovig AutoinjectorErenumab-Aooe | 17 | $27,925 |
| NuedextaDextromethorphan Hbr/Quinidine | 16 | $27,043 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 28 | $25,244 |
| XcopriCenobamate | 20 | $21,349 |
| XareltoRivaroxaban | 24 | $20,204 |
| QuliptaAtogepant | 13 | $16,118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt, Eliquis | $307 | $226,114168 claims |
| AbbVieUbrelvy, Qulipta | $367 | $101,20769 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $297 | $90,46312 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $371 | $88,09413 claims |
| MDD US Operations, LLCGocovri | $230 | $67,29321 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $117 | $27,04316 claims |
| SK Life Science, Inc.Xcopri | $407 | $21,34920 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $42 | $14,55712 claims |
| AstraZenecaBrilinta | $227 | $12,62124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 93 neurology providers in Arkansas.
Other neurology in Fort Smith
- Steve-Felix BelingaFort Smith$183K
- William KnubleyFort Smith$26K
- Tonya PhillipsFort Smith$17K
- Janice KeatingFort Smith$16K
- Satish GaddamFort Smith$14K
- John KareusFort Smith$3K
- Jon GustafsonFort Smith$2K
- Pradeep KumbhamFort Smith$2K
- Kathryn ChenaultSherwood$532K
- Michael MorseFayetteville$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.